Revolution Medicines (RVMD) Scheduled to Post Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $0.81 million. Revolution Medicines’s revenue was down 73.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.92) earnings per share. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Stock Down 0.0 %

Revolution Medicines stock traded down $0.01 during mid-day trading on Tuesday, reaching $55.86. 291,620 shares of the company traded hands, compared to its average volume of 1,317,409. The firm’s 50 day moving average price is $46.26 and its 200 day moving average price is $42.62. Revolution Medicines has a 52-week low of $18.79 and a 52-week high of $56.56.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. JPMorgan Chase & Co. cut their price objective on Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Bank of America upped their price objective on shares of Revolution Medicines from $48.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Needham & Company LLC reissued a “buy” rating and issued a $61.00 price target on shares of Revolution Medicines in a research report on Thursday, October 24th. Wedbush restated an “outperform” rating and issued a $59.00 price target on shares of Revolution Medicines in a research note on Thursday, August 8th. Finally, Oppenheimer lifted their price objective on Revolution Medicines from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $56.75.

Insider Buying and Selling

In other Revolution Medicines news, COO Margaret A. Horn sold 50,000 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $50.34, for a total value of $2,517,000.00. Following the transaction, the chief operating officer now directly owns 132,320 shares of the company’s stock, valued at approximately $6,660,988.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Revolution Medicines news, COO Margaret A. Horn sold 50,000 shares of the business’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $50.34, for a total transaction of $2,517,000.00. Following the completion of the sale, the chief operating officer now owns 132,320 shares of the company’s stock, valued at approximately $6,660,988.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mark A. Goldsmith sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $44.93, for a total value of $449,300.00. Following the completion of the transaction, the insider now directly owns 300,170 shares in the company, valued at $13,486,638.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,866 shares of company stock worth $6,355,624. 8.00% of the stock is owned by corporate insiders.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.